Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(625)
•••
Comment by KayakerBCon Aug 03, 2016 11:57am
48 Views
Post# 25106538

RE:RE:RE:RE:RE:RE:RE:RE:RE:Think about this..

RE:RE:RE:RE:RE:RE:RE:RE:RE:Think about this..
Me: Uh, I didn't say they are close to a deal. You seem to be a tad bit confused.

Junior: There you have it. The first one to walk back their 2016 prediction.

As I said, you're a tad bit confused.  There's 5 months left in the year. "Close to a deal" is your prediction of a deal by the end of July.  I guess we're just a few days late?

Anyhow, that's pretty laughable.  In June you said, that nothing would happen this year.

July 20th you said, "Look at the low of the day today. We will never see that again. This will run hard into a deal by end of this month".

Now we're in August and you're back to saying nothing will happen this year.

Should we look forward to yet another reversal in September? LOL.



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities